Across TCGA pan-cancer cohorts, CENPO Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CENPO data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CENPO Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CENPO expression acts as an unfavorable survival marker.
LUAD are the cancer types where CENPO Mutation most reproducibly stratifies survival.